Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy and the postpartum period. These drugs are capable of crossing the placenta and being transferred to the newborn during lactation. This report reviews the available information regarding the effects of SSRIs on the fetus and newborn; including long-term neurodevelopmental outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Maternal depression and anxiety are two of the highest reported complications of pregnancy (Lattimore et al. 2005)”
From Pilot early intervention antenatal group program for pregnant women with anxiety and depression (2014) · cites this paper as Lattimore et al. 2005
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“The lifetime risk for depression in women varies from 10 to 30%, with peak prevalence during the childbearing years.(1,2) Studies of postpartum depression suggest a 10 to 15% incidence in all parturients, making it one of the most common complications of pregnancy.”
Background(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Depressive Symptoms among Pregnant Women Screened in Obstetrics Settings
Marcus, S. M., Flynn, H. A., Blow, F. C., & Barry, K. L. (2003) · Journal of Women's Health · doi:10.1089/154099903765448880 · Cited by 742 · cited 1×
“In addition, infants of chronically depressed mothers score inferiorly on the Bayley Mental and Motor Scales, achieve lower growth percentiles at 1 year of age,(4) and have delayed linguistic development and behavioral difficulties.(5) Depressed women have elevated levels norepinephrine and cortisol as markers of stre…”
BackgroundBirth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Depression and anxiety in early pregnancy and risk for preeclampsia
Kurki, T. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00602-x · Cited by 690
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612 · cited 1×
“This is their major advantage over the tricyclic antidepressants (TCA), and the reason for their increased tolerance and fewer adverse side effects.(12)”
BackgroundNeurodevelopment of Children Exposed in Utero to Antidepressant Drugs
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G. W., Kulin, N., & Koren, G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360404 · Cited by 573
Field, T. (1995) · Infant Behavior and Development · doi:10.1016/0163-6383(95)90003-9 · Cited by 524
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., & Koren, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1889 · Cited by 441 · cited 4×
“Recently, in a prospective cohort trial, Nulman et al.34,36 evaluated IQ, language development, and temperament in children exposed to TCAs or SSRIs in the first trimester only, and also throughout pregnancy, compared to infants born to mothers who were not depressed and were not exposed to any known teratogenic medic…”
BackgroundResultInfluentialKulin, N. A., Pastuszak, A., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormond, K., Matsui, D., Stein-Schechman, A. K., Cook, L., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 424
Research works printed but not linked: 6
- Zeskind PS, Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375. · DOI · Paper page
- Costei AM, Kozer E, Ho T, Ito S, Koren G . Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–1132. · DOI · Paper page
- Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815. · DOI · Paper page
- Chambers C, Dick LM, Felix RJ, Johnson KA, Jones KL . Pregnancy Outcome in women who use sertraline. Teratology 1999;59:376.
- Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248. · DOI · Paper page
- Zeskind PS, Oberlander TF, Grunau RE, et al. Continuing effects of prenatal SSRI exposure detected by spectral analysis of infant cry sounds at two months of age. Pediatr Res 2005;57:1624A.
Cited by
Donofrio, M. T., Moon-Grady, A. J., Hornberger, L. K., Copel, J. A., Sklansky, M. S., Abuhamad, A., Cuneo, B. F., Huhta, J. C., Jonas, R. A., Krishnan, A., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437597.44550.5d · Cited by 1,275
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“neonatal adaptation syndrome (PNAS) [1121-1123], while”
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“, 2006) malformations, but one found evidence that SSRI use late in pregnancy was associated with subtle adverse effects (serotonergic overstimulation, withdrawal syndromes, long term neurobehavioural effects) in newborns (Lattimore et al., 2005).”
BackgroundRoss, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
Selective serotonin reuptake inhibitors and adverse pregnancy outcomes
Wen, S. W., Yang, Q., Garner, P., Fraser, W., Olatunbosun, O., Nimrod, C., & Walker, M. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.02.019 · Cited by 234
Davis, R. L., Rubanowice, D., McPhillips, H., Raebel, M. A., Andrade, S. E., Smith, D., Yood, M. U., & Platt, R. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1462 · Cited by 203
“The longterm effects of SSRI exposure on neurobehavioral development are unknown.(14,16,21,22) In a previous study,(6) we used data from five health maintenance organizations (HMOs) participating in the HMO Research Network’s Center for Education and Research on Therapeutics (CERTs) project to characterize medication…”
MethodPopa, D., Léna, C., Alexandre, C., & Adrien, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4006-07.2008 · Cited by 184
“There is growing evidence that the susceptibility to sleep disorders and depression could result, at least in part, from serotonin-dependent developmental alterations (Ansorge et al., 2004; Lattimore et al., 2005; Alexandre et al., 2006).”
BackgroundStewart, D. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1102730 · Cited by 183
Huang, H., Coleman, S., Bridge, J. A., Yonkers, K., & Katon, W. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.08.002 · Cited by 180
“08) [49].”
Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Eady, A., Tomlinson, G., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07967 · Cited by 180
Non, A. L., Binder, A. M., Kubzansky, L. D., & Michels, K. B. (2014) · Epigenetics · doi:10.4161/epi.28853 · Cited by 172
International Encyclopedia of Rehabilitation
Tower, K. (2010) · Cited by 173
Winklbaur, B., Kopf, N., Ebner, N., Jung, E., Thau, K., & Fischer, G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02283.x · Cited by 171
“Physicians frequently prescribe and administer this group of substances to pregnant patients [87].”
BackgroundInfluentialUntreated Depression During Pregnancy and Its Effect on Pregnancy Outcomes: A Systematic Review
Jahan, N., Went, T. R., Sultan, W., Sapkota, A., Khurshid, H., Qureshi, I. A., & Alfonso, M. (2021) · Cureus · doi:10.7759/cureus.17251 · Cited by 163
“These medications have been shown to pass the placenta, and serotonin is essential for embryonic brain development [27].”
Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135
Ferreira, E., Carceller, A. M., Agogué, C., Martin, B. Z., St-André, M., Francoeur, D., & Bérard, A. (2007) · Pediatrics · doi:10.1542/peds.2006-2133 · Cited by 135
Antidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
“…OR 2.06 (95%CI 1.58–2.69) TCA OR 2.50 (95%CI 1.87–3.4) Zeskind et al., 2004 [55] Retrospective cohort SSRIs n 17 Controls n 17 Increased prematurity p 0.019 Lattimore et al., 2005 [52] Meta-analysis SSRIs n 511 Controls n 438 OR 2.03 (95%CI 1.61-2.6) Djulus et al., 2006 [29] Prospective cohort…”
BackgroundInfluentialWu, Y., De Asis-Cruz, J., & Limperopoulos, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02449-0 · Cited by 124
“This attenuated response may result from increased serotonin (5-HT) and GABA agonists in the fetal brain under SSRI exposure [166, 168].”
BackgroundCharlton, R., Jordan, S., Pierini, A., Garne, E., Neville, A., Hansen, A., Gini, R., Thayer, D., Tingay, K., Puccini, A., et al. (2015) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.13143 · Cited by 121
Olivier, J. D. A., Åkerud, H., Kaihola, H., Pawluski, J. L., Skalkidou, A., Högberg, U., & Sundström-Poromaa, I. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00073 · Cited by 107
“…increased risk of neonatal seizures, longer hospital stays, and NICU admissions after SSRI use during pregnancy (Simon et al., 2002; Källén, 2004; Lattimore et al., 2005; Oberlander et al., 2006; Wen et al., 2006; Cole et al., 2007; Davis et al., 2007), although an increased risk for NICU…”
BackgroundCerritelli, F., Frasch, M. G., Antonelli, M. C., Viglione, C., Vecchi, S., Chiera, M., & Manzotti, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.721605 · Cited by 108
“, 2012) and poor neonatal adaptation syndrome (Lattimore et al., 2005; Sivojelezova et al., 2005).”
BackgroundInfluentialMaternal psychological distress during pregnancy and childhood health outcomes: a narrative review
Vehmeijer, F. O. L., Guxens, M., Duijts, L., & El Marroun, H. (2019) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000557 · Cited by 107
Serotonergic transcriptional programming determines maternal behavior and offspring survival
Lerch-Haner, J. K., Frierson, D., Crawford, L. K., Beck, S. G., & Deneris, E. S. (2008) · Nature Neuroscience · doi:10.1038/nn.2176 · Cited by 106
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Postpartum Depression: An Update
Friedman, S. H., & Resnick, P. J. (2009) · Women's Health · doi:10.2217/whe.09.3 · Cited by 100
Fetal Effects of Psychoactive Drugs
Salisbury, A. L., Ponder, K. L., Padbury, J. F., & Lester, B. M. (2009) · Clinics in Perinatology · doi:10.1016/j.clp.2009.06.002 · Cited by 97
Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus
Mulder, E. J. H., Ververs, T. F., de Heus, R., & Visser, G. H. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.67 · Cited by 103
“It is unknown whether the neonatal problems result from acute cessation of SSRI exposure at birth (withdrawal), or result from alterations in fetal neurobehavioral development secondary to sustained prenatal exposure (ie, an in utero effect; Lattimore et al, 2005).”
BackgroundPrenatal Exposure to Fluoxetine Induces Fetal Pulmonary Hypertension in the Rat
Fornaro, E., Li, D., Pan, J., & Belik, J. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-163oc · Cited by 96
“Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is often prescribed as an antidepressant to pregnant women (1).”
BackgroundMaternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation
Sie, S. D., WENNINK, J. M. B., van Driel, J. J., Winkel, A. T., Boer, K., Casteelen, G., & van Weissenbruch, M. M. (2012) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2011-214239 · Cited by 98
Andalib, S., Emamhadi, M. R., Yousefzadeh-Chabok, S., Shakouri, S. K., Høilund-Carlsen, P. F., Vafaee, M. S., & Michel, T. M. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.06.001 · Cited by 86
“They cross the placenta and are transferred to the newborn over lactation [20].”
BackgroundMaschi, S., Clavenna, A., Campi, R., Schiavetti, B., Bernat, M., & Bonati, M. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01518.x · Cited by 80
Does Fetal Exposure to SSRIs or Maternal Depression Impact Infant Growth?
Wisner, K. L., Bogen, D. L., Sit, D., McShea, M., Hughes, C., Rizzo, D., Confer, A., Luther, J., Eng, H., & Wisniewski, S. W. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11121873 · Cited by 78
Ellfolk, M. A., & Malm, H. T. (2010) · Reproductive Toxicology · doi:10.1016/j.reprotox.2010.04.015 · Cited by 86
Vlenterie, R., van Gelder, M. M. H. J., Anderson, H. R., Andersson, L., Broekman, B. F. P., Dubnov‐Raz, G., Marroun, H. E., Ferreira, E., Fransson, E., der Heijden, F. M. M. A. V., et al. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004538 · Cited by 90
Cipriani, A., Geddes, J. R., Furukawa, T. A., & Barbui, C. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200903 · Cited by 73
“Cigarette smoking is known to adversely affect infant growth in utero, and alcohol abuse has been associated with prematurity and small-for-gestational age infants.(30) In addition, almost all the included studies compared SSRI-exposed women with healthy control populations having no psychiatric diagnosis, even though…”
BackgroundFetal and Neonatal Effects of Maternal Drug Treatment for Depression
Belik, J. (2008) · Seminars in Perinatology · doi:10.1053/j.semperi.2008.08.001 · Cited by 77
Davidson, S., Prokonov, D., Taler, M., Maayan, R., Harell, D., Gil‐Ad, I., & Weizman, A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e318193594a · Cited by 71
Are exposure-based cognitive behavioral therapies safe during pregnancy?
Arch, J. J., Dimidjian, S., & Chessick, C. (2012) · Archives of Women's Mental Health · doi:10.1007/s00737-012-0308-9 · Cited by 71
“Finally, the most common treatment for anxiety disorders— pharmacotherapy—carries a wide range of potential risks during pregnancy (e.g., Lattimore et al. 2005; Mintzes and Jureidini 2008), underscoring the need for research on safe and effective alternatives.”
Soubry, A., Murphy, S., Huang, Z., Murtha, A., Schildkraut, J., Jirtle, R., Wang, F., Kurtzberg, J., Demark-Wahnefried, W., Forman, M., et al. (2011) · Clinical Epigenetics · doi:10.1186/1868-7083-3-2 · Cited by 66
“1% to 14%; this variation depends on the study design and the trimester of pregnancy [41,42,7].”
BackgroundA 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Jordan, S. E., Morris, J. K., Davies, G. I., Tucker, D., Thayer, D. S., Luteijn, M., Morgan, M., Garne, E., Hansen, A. V., Klungsøyr, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165122 · Cited by 75
Anxiety Disorders in Pregnancy and the Postpartum Period
Anniverno, R., Bramante, A., Mencacci, C., & Durbano, F. (2013) · New Insights into Anxiety Disorders · doi:10.5772/52786 · Cited by 62
“However some data evidenced an association between SSRI use and negative obstetric outcome like mild degrees of preterm birth and low birth weight [47; 54-56], and there are adverse neonatal outcomes reports including mild degrees of poor neonatal adaptation (neonatal withdrawal syndrome) follow‐ ing SSRI exposure [47…”
ResultAllegaert, K., van Schaik, R. H. N., Vermeersch, S., Verbesselt, R., Cossey, V., Vanhole, C., van Fessem, M., Hoon, J. N. J. M. D., & van den Anker, J. N. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e31816ff712 · Cited by 64
“There is still controversy whether symptoms observed in neonates born to mothers to whom SSRI during pregnancy were administered, reflect neonatal withdrawal (enhanced clearance) or are the manifestation of persistent high SSRI concentrations with toxicity due to limited clearance (26).”
BackgroundComplex Challenges in Treating Depression During Pregnancy
Chaudron, L. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040440 · Cited by 60
Kautzky, A., Slamanig, R., Unger, A., & Höflich, A. S. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13367 · Cited by 65
Early predictors of perinatal brain damage: the role of neurobiomarkers
Bersani, I., Pluchinotta, F. R., Dotta, A., Savarese, I., Campi, F., Auriti, C., Chuklantseva, N., Piersigilli, F., Gazzolo, F., Varrica, A., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0725 · Cited by 62
Gentile, S. (2010) · CNS Spectrums · doi:10.1017/s1092852900027449 · Cited by 53
Zhao, X., Liu, Q., Cao, S., Pang, J., Zhang, H., Feng, T., Deng, Y., Yao, J., & Li, H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.061 · Cited by 57
de Vries, N. K. S., van der Veere, C. N., Reijneveld, S. A., & Bos, A. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064654 · Cited by 50
“[10,14,15,28–31] In SSRI-exposed foetuses, a dose-related response was also found by Mulder et al .”
Prady, S. L., Hanlon, I., Fraser, L. K., & Mikocka-Walus, A. (2017) · Archives of Women's Mental Health · doi:10.1007/s00737-017-0780-3 · Cited by 50
“However, among the numerous examples of previous systematic reviews on the subject (Bromley et al. 2012; Fenger-Gron et al. 2011; Gentile and Galbally 2011; Lattimore et al. 2005; McDonagh et al. 2014; Previti et al. 2014; Ross et al. 2013; Simoncelli et al. 2010; Udechuku et al. 2010), only one (Ross et al.”
BackgroundMcKillop, H. N., & Connell, A. M. (2018) · Developmental Psychobiology · doi:10.1002/dev.21630 · Cited by 52
Grzeskowiak, L. E., Morrison, J. L., Henriksen, T. B., Bech, B. H., Obel, C., Olsen, J., & Pedersen, L. (2015) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.13611 · Cited by 50
Prenatal and Perinatal Risk Factors
Winiarski, D. A., Hendrix, C. L., Smearman, E., & Brennan, P. A. (2017) · Wiley eBooks · doi:10.1002/9781119092254.ch12 · Cited by 48
de Oliveira, J. F., Ponte, B., Barbosa, A. P. M., Veríssimo, L. F., Gomes, M. V., Pelosi, G. G., de Britto, L. R. G., & Moreira, E. G. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.064 · Cited by 61
Postpartum Depression: Etiology, Treatment, and Consequences for Maternal Care
Dimcea, D. A., Petca, R., Dumitrașcu, M. C., Şandru, F., Mehedințu, C., & Petca, A. T. (2024) · Diagnostics · doi:10.3390/diagnostics14090865 · Cited by 80
“Paroxetine and sertraline are the safest selective serotonin reuptake inhibitors during breastfeeding [92].”
BackgroundBoas, G. R. V., Lavorato, S. N., Paes, M. M., Galdino, P. M., Rescia, V. C., Cunha, M. S., de Magalhães-Filho, M. F., Ponsoni, L. F., de Carvalho, A. A. V., de Lacerda, R. B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14020148 · Cited by 49
“The ability of these drugs to block this transporter without affecting other neuroreceptors made them stand out from other antidepressant therapies, with fewer adverse and side effects [39].”
BackgroundCantarutti, A., Merlino, L. G., Monzani, E., Giaquinto, C., & Corrao, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168115 · Cited by 45
Martinez‐Paredes, J. F., & Jácome-Pérez, N. (2017) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2017.07.003 · Cited by 75
Exploring heterogeneity in meta‐analyses: needs, resources and challenges
Xu, H., Platt, R. W., Luo, Z., Wei, S. Q., & Fraser, W. D. (2008) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2007.00908.x · Cited by 46
Pilot early intervention antenatal group program for pregnant women with anxiety and depression
Thomas, N., Komiti, A., & Judd, F. (2014) · Archives of Women's Mental Health · doi:10.1007/s00737-014-0447-2 · Cited by 37
“Maternal depression and anxiety are two of the highest reported complications of pregnancy (Lattimore et al. 2005) and by third trimester prevalence rates often mirror those reported in the first weeks post birth.”
BackgroundResultSafety of Psychotropic Medications During Pregnancy
Raffi, E. R., Nonacs, R. M., & Cohen, L. S. (2019) · Clinics in Perinatology · doi:10.1016/j.clp.2019.02.004 · Cited by 45
Pharmacological Aspects of Neonatal Antidepressant Withdrawal
ter Horst, P. G. J., Jansman, F. G. A., van Lingen, R. A., Smit, J.-P., de Jong-van den Berg, L. T. W., & Brouwers, J. R. B. J. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181676be8 · Cited by 37
“Respiratory distress Fluoxetine (68,120,121,160) Clomipramine (93,159,162,163,167)”
InfluentialHutchison, S. M., Mâsse, L. C., Pawluski, J. L., & Oberlander, T. F. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.02.004 · Cited by 41
“SSRIs have been related to significantly poorer motor quality compared to infants without exposure [30, 117- 121], even when controlling for pre- and postnatal depression, smoking, and alcohol use [19].”
BackgroundGestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review
Broy, P., & Bérard, A. (2010) · Current Drug Delivery · doi:10.2174/156720110790396508 · Cited by 38
“and patients tend to be compliant [32, 34].”
BackgroundA review of the use of psychotropic medication in pregnancy
Galbally, M., Snellen, M., & Lewis, A. J. (2011) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32834b92f3 · Cited by 41
Alterations to Embryonic Serotonin Change Aggression and Fearfulness
Dennis, R. L., Fahey, A. G., & Cheng, H. W. (2013) · Aggressive Behavior · doi:10.1002/ab.21459 · Cited by 39
“Mice exposed prenatally to SSRIs (selective 5‐HT reuptake inhibitors, functionally as 5‐HTagonists) exhibited increased anxiety *Correspondence to: Heng‐wei Cheng, Livestock Behavior Research Unit, USDA‐ARS, Purdue University, W. Lafayette, IN 47907.”
BackgroundPreviti, G., Pawlby, S. J., Chowdhury, S., Aguglia, E., & Pariante, C. M. (2014) · Archives of Women s Mental Health · doi:10.1007/s00737-014-0457-0 · Cited by 39
“There is some evidence to show that therapies other than drugs are effective forms of treatment for the mother’s mental illness, but to our knowledge, there are no recent systematic reports on the their impact of antidepressant treatment on the newborn focusing on neurodevelopment (Chaudron 2013; Gentile and Galbally…”
BackgroundGrzeskowiak, L. E., Gilbert, A. L., & Morrison, J. L. (2011) · Drug Safety · doi:10.2165/11593130-000000000-00000 · Cited by 35
Grzeskowiak, L. E., Gilbert, A. L., & Morrison, J. L. (2012) · Reproductive Toxicology · doi:10.1016/j.reprotox.2012.03.003 · Cited by 39
Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders
Liu, Q., Chen, M.-X., Sun, L., Wallis, C. U., Zhou, J., Ao, L., Li, Q., & Sham, P. C. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i2.55 · Cited by 32
Tran, H., & Robb, A. S. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.08.010 · Cited by 28
Pharmacological Treatment of Panic Disorder
Bandelow, B., Baldwin, D. S., & Zwanzger, P. (2013) · Modern trends in psychiatry · doi:10.1159/000351953 · Cited by 31
Serotonin Reuptake Inhibitor-Induced Perinatal Complications
Gentile, S. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709020-00003 · Cited by 28
How to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 33
Şahingöz, M., Yüksel, G., Karşıdağ, Ç., Uğuz, F., Sönmez, E. Ö., Annagür, B. B., & Annagür, A. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000077 · Cited by 26
Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome
Malm, H. T. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31826d07ea · Cited by 27
Grzeskowiak, L. E., Gilbert, A. L., Sørensen, T. I. A., Olsen, J., Sørensen, H. T., Pedersen, L. H., & Morrison, J. L. (2013) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.08.005 · Cited by 25
Frayne, J. S., Nguyen, T., Bennett, K., Allen, S., Hauck, Y. L., & Liira, H. (2017) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12621 · Cited by 27
The mothers, Omega-3 and mental health study
Mozurkewich, E., Chilimigras, J. L., Klemens, C., Keeton, K., Allbaugh, L. J., Hamilton, S., Berman, D. R., Vázquez, D. M., Marcus, S. M., Djurić, Z., et al. (2011) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-11-46 · Cited by 26
“In a meta-analysis of available studies on SSRI use during pregnancy and effects on the fetus and newborn, Lattimore et al found that infants exposed to SSRIs in utero are more likely to be low birth weight and more likely to be admitted to a SCN/NICU at birth than infants born to mothers not on these medications[20].”
Selective serotonin reuptake inhibitors in pregnancy and infant outcomes
Jefferies, A. L. (2011) · Paediatrics & Child Health · doi:10.1093/pch/16.9.562 · Cited by 24
“A syndrome of respiratory, motor, central nervous system and gastrointestinal symptoms, including tachypnea, cyanosis, jitteriness/tremors, increased muscle tone, and feeding disturbance has been noted in 10% to 30% of babies exposed to SSRIs in utero [16][18][20][21] [22].”
BackgroundDubrall, D., Leitzen, S., Toni, I., Stingl, J., Schulz, M., Schmid, M. C., Neubert, A. C., & Sachs, B. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00520-y · Cited by 24
The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review
Bellantuono, C., Bozzi, F., Orsolini, L., & Catena-Dell’Osso, M. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2265 · Cited by 26
“retrospective cohort and case-control studies, population-based pregnancy registries, small case-series and case reports, as pregnant women are systematically excluded from randomized clinical trials involving ADs (Lattimore et al., 2005; Grzeskowiak et al., 2011).”
BackgroundInfluentialTreatment of nonpsychotic major depression during pregnancy: patient safety and challenges
EPSTEIN, R. A., Moore, K. M., & Bobo, W. V. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43308 · Cited by 24
Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight
Grzeskowiak, L. E., Gilbert, A. L., & Morrison, J. L. (2012) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174411000808 · Cited by 23
Munkboel, C. H., Larsen, L. W., Weisser, J. J., Kristensen, D. M., & Styrishave, B. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy059 · Cited by 24
Brain Damage - Bridging Between Basic Research and Clinics
González-Quevedo, A. (2012) · InTech eBooks · doi:10.5772/2174 · Cited by 22
“Studies to evaluate the neurotoxicity of SSRI’s identified a number of agespecific and site-specific effects in the fetal rat brain, especially related to the limbic system (Lattimore et al 2005).”
BackgroundNeonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure
Corti, S., Pileri, P., Mazzocco, M. I., Mandò, C., Moscatiello, A. F., Cattaneo, D., Cheli, S., Baldelli, S., Pogliani, L., Clementi, E., et al. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00309 · Cited by 25
Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach
Uğuz, F. (2015) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1673 · Cited by 20
Treating Depression during Pregnancy: Are We Asking the Right Questions?
Angelotta, C., & Wisner, K. L. (2017) · Birth Defects Research · doi:10.1002/bdr2.1074 · Cited by 22
Bellissima, V., Visser, G. H. A., Ververs, T. F., van Bel, F., Termote, J. U. M., van der Heide, M., Florio, P., Volti, G. L., & Gazzolo, D. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.604931 · Cited by 23
“In addition, during pregnancy and during the postpartum period 10% of women will present a major depressive disorder [2].”
BackgroundVenkatesh, K. K., Castro, V. M., Perlis, R. H., & Kaimal, A. J. (2017) · Journal of Perinatology · doi:10.1038/jp.2017.92 · Cited by 20
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
“, 2005 [130] Meta-analysis of prospective cohort studies SSRI (III trimester exposure) Non-significant PNA risk (OR = 4.”
BackgroundInfluentialMaternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy
Velasquez, J. C., Goeden, N., Herod, S. M., & Bonnin, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00287 · Cited by 17
Hogue, A. N., Temple, M. E., Lagzdins, M., Worley, S., Scwersenski, J., Floyd, R., & Saker, F. (2017) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-16133 · Cited by 16
Neonatal outcomes in pregnant women with untreated and treated panic disorder
Uğuz, F., Yüksel, G., Onur, Ö. Ş., Karşıdağ, Ç., Gezginç, K., & Arpacı, N. (2018) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.10.001 · Cited by 19
Taouk, L. H., Matteson, K. A., Stark, L. M., & Schulkin, J. A. (2017) · Archives of Women s Mental Health · doi:10.1007/s00737-017-0760-7 · Cited by 18
“Although available data suggests low overall risk of teratogenic effects due to antidepressant use, risks for harm have been found (Patel et al. 2011; Reefhuis et al. 2015; Lattimore et al. 2005), and the FDA’s current position is that the “potential risk with SSRI use during pregnancy remains unknown” (US FDA 2012).”
Martinez‐Paredes, J. F., & Jácome-Pérez, N. (2019) · Revista Colombiana de Psiquiatría (English ed ) · doi:10.1016/j.rcpeng.2017.07.002 · Cited by 41
Perinatal depression and psychosis: an update
Doyle, M., Carballedo, A., & O’Keane, V. (2015) · BJPsych Advances · doi:10.1192/apt.bp.112.010900 · Cited by 18
Metadata
- Authors
- Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Perinatology
- Published
- 2005-07-14
- Volume
- 25
- Issue
- 9
- Pages
- 595-604
- ISSN
- 0743-8346 (ISSN-L)
- 1476-5543
- OpenAlex
- W2040155286
- Cited by
- 189
- References
- 55
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 14 · 2020: 6 · 2019: 14 · 2018: 9 · 2017: 13 · 2016: 7 · 2015: 11 · 2014: 11 · 2013: 17 · 2012: 15
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (MH065062, R21MH065062, MH068489, R21MH068489)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- selective serotonin reuptake inhibitors, pregnancy, fetal effects, neonatal outcomes, placental transfer, breastfeeding, maternal depression, postpartum depression, neurodevelopmental outcomes, antidepressant safety
- MeSH terms
- Child Development, Female, Fetus, Humans, Infant, Newborn, Maternal-Fetal Exchange, Pregnancy, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.